Theravance Could Face Prospect Of Another Trial For Vibativ In HAP
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Theravance could potentially have to conduct a new clinical trial to gain FDA approval for a nosocomial pneumonia indication for the firm's antibiotic Vibativ